Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stephens & Co. Reiterates Overweight on Ardent Health Partners, Maintains $24 Price Target

Author: Benzinga Newsdesk | August 15, 2024 08:37am
Stephens & Co. analyst Scott Fidel reiterates Ardent Health Partners (NYSE:ARDT) with a Overweight and maintains $24 price target.

Posted In: ARDT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist